The Recall Desk
HighFDA (Drugs)·D-0566-2025·Announced 2025-08-13

Doxepin hydrochloride capsules exceed the interim nitrosamine impurity limit

Doxepin Hydrochloride Capsules USP 10 mg from Alembic are being recalled because a nitrosamine drug substance related impurity was present above the proposed interim limit. 9,492 bottles affected.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Risk-of-harm product: a nitrosamine impurity measured above the named interim limit, with no injury reported in the source.

Plain-English summary

Doxepin Hydrochloride Capsules, USP, 10 mg, 100 capsules per bottle, prescription only, manufactured by Alembic Pharmaceuticals Limited of Gujarat, India for Alembic Pharmaceuticals, Inc. of Bedminster, New Jersey, is being recalled. The action covers 9,492 bottles.

The stated reason is CGMP deviations: the presence of a nitrosamine drug substance related impurity above the proposed interim limit. The FDA classified the action as Class II.

The affected lot is 2305015142, expiring 9/30/2025. Distribution was nationwide in the USA.

Patients holding the affected lot should speak to their pharmacist or prescriber before stopping treatment, and pharmacies should follow the instructions issued by the manufacturer.

The recalled product

Product
DOXEPIN HYDROCHLORIDE (DOXEPIN HYDROCHLORIDE)
Brand
DOXEPIN HYDROCHLORIDE
Manufacturer
Alembic Pharmaceuticals Limited
Hazard
  • nitrosamine
  • impurity-limit
  • cgmp-deviation
  • class-ii

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot: 2305015142
  • Exp. Date: 9/30/2025

UPCs (1)

  • 0362332645312

Distribution

Distributed nationwide across the United States.